PDPN and cancer: We developed CasMabs against podoplanin (LpMab-2 and LpMab-23 [30]), podocalyxin (PcMab-6 [31]), and HER2 (H2Mab-250 [22]) by evaluating the reactivity against cancer and normal cells in flow cytometry.